Form 4: EyePoint Director Sells Shares Under 10b5-1 Plan

EyePoint Pharmaceuticals Director Nancy Lurker sold 9,300 shares of common stock for a weighted average price of $15.1051 per share.

Summary

• Nancy Lurker, a Director of EyePoint Pharmaceuticals, Inc. (EYPT), reported a sale of common stock.
• The transaction involved the disposition of 9,300 shares of common stock.
• The shares were sold on December 4, 2025, at a weighted average price of $15.1051 per share.
• The sale was executed in multiple transactions with prices ranging from $14.95 to $15.36.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following the reported transaction, Nancy Lurker directly beneficially owns 206,547 shares of common stock.
• Additionally, 126,889 shares are indirectly held by a Family Trust for the benefit of her children, for which she disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider stock transaction under a pre-arranged 10b5-1 plan, which is generally considered neutral in sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a director's personal stock holdings and transactions, which can inform investment decisions.

Key Dates

Keywords

EyePoint Pharmaceuticals, EYPT, Insider Trading, Form 4, Stock Sale, Nancy Lurker, Director, 10b5-1 Plan